The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Axial Spondyloarthritis (axSpA) Market Between 2026 And 2030?

The axial spondyloarthritis (axspa) market size has demonstrated robust growth in recent years. It is anticipated to expand from $6.56 billion in 2025 to $7.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be primarily ascribed to factors like increasing awareness of inflammatory spinal disorders, the broader application of TNF inhibitors, enhanced availability of diagnostic imaging, growth within rheumatology specialty care, and initiatives aimed at improving treatment adherence.

The axial spondyloarthritis (axspa) market is set to experience substantial expansion in the upcoming years, with its value projected to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is fueled by factors such as the increasing acceptance of JAK inhibitors and IL therapies, a rise in investments directed towards personalized medicine, the broadening of early screening initiatives, the expanding application of digital platforms for disease monitoring, and continuous advancements in biologic drug development. Noteworthy trends expected over this period include the increased adoption of biologic therapies, a growing reliance on targeted anti-inflammatory drugs, a heightened focus on early diagnosis and disease monitoring, the proliferation of personalized treatment approaches, and enhanced integration of digital health tools.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

Which Core Factors Are Supporting The Expansion Of The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpa) market is anticipated to expand, driven by the growing aging population. This demographic trend signifies an increasing proportion of older individuals within a population. Effectively managing axSpA in older adults offers several advantages, such as enhanced joint function and mobility, better quality of life, protection against spinal structural damage, lower healthcare expenditures, disability prevention, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported 11 million individuals aged over 65 in England in 2023. This number is projected to rise by 10% in the next five years and by 32% by 2043 (equivalent to 1.1 and 3.5 million people, respectively). Furthermore, the 85+ age group, which typically requires the most health and care services, is expected to experience swift growth, increasing by 8.2% over the next five years and by 62.7% by 2043 (representing 126,000 and 956,000 people, respectively). Consequently, the expanding aging demographic is a significant impetus behind the growth of the axial spondyloarthritis (axSpa) market.

How Is Segment Classification Applied In The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Future Of The Axial Spondyloarthritis (axSpA) Market?

Leading companies within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, particularly next-generation biologic drug therapies, to address the increasing need for effective treatments that target inflammation and improve long-term disease control. These biologic therapies modulate specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily alleviate symptoms without directly influencing underlying immune drivers. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, secured marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is indicated for treating adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who show objective signs of inflammation, as evidenced by elevated C-reactive protein. These European Union (EU) authorizations represent the drug’s first global marketing licenses specifically for axial spondyloarthritis.

Who Are The Companies Shaping The Axial Spondyloarthritis (axSpA) Market Landscape?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Access The Complete Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What Is The Largest Regional Market In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Axial Spondyloarthritis (axSpA) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Osteoarthritis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Cervical Spondylosis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model